The Lancet Psychiatry Publishe – GuruFocus.com

Related Articles:

• Persistent Psychiatric and Neurological Sequalae Observed at 6 Months After COVID-19 Infection April 12, 2021 Substantial psychiatric and neurological morbidities persisted among many for 6 months following a SARS-CoV-2 infection, especially among those who were severely ill. These findings, from a retrospective cohort study, were published in Lancet Psychiatry. Researchers from University of Oxford analyzed data from The TriNetX Analytics Network which included electronic health records from 81 million patients, primarily collected in the United…
• AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders - GuruFocus.com September 23, 2019 AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders  GuruFocus.comFinal data from Phase 1b study evaluating subcutaneous infusion of investigational medicine ABBV-951 in patients with advanced Parkinson's disease (PD) to ...
• NUPLAZID® (pimavanserin) Effic - GuruFocus.com June 3, 2021 NUPLAZID® (pimavanserin) Effic  GuruFocus.com
• Cortexyme to Present Results f - GuruFocus.com September 27, 2021 Cortexyme to Present Results f  GuruFocus.com
• BioVie Announces the Appointment of a New Chief Medical Officer - GuruFocus.com November 1, 2021 BioVie Announces the Appointment of a New Chief Medical Officer  GuruFocus.com
• Trial Lawyer Majed Nachawati A - GuruFocus.com November 3, 2021 Trial Lawyer Majed Nachawati A  GuruFocus.com
• Halberd Follow-up Verification - GuruFocus.com December 6, 2021 Halberd Follow-up Verification  GuruFocus.com
• Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference - GuruFocus.com April 21, 2022 Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference  GuruFocus.com
• Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress - GuruFocus.com May 16, 2022 Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress  GuruFocus.com
• Anavex Life Sciences to Present at the HC Wainwright Global Investment Conference 2022 - GuruFocus.com June 18, 2022 Anavex Life Sciences to Present at the HC Wainwright Global Investment Conference 2022  GuruFocus.com
• Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson's Disease and Movement Disorders Congress - GuruFocus.com June 18, 2022 Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson's Disease and Movement Disorders Congress  GuruFocus.com
• Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ - GuruFocus.com June 18, 2022 Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ  GuruFocus.com
• Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study - GuruFocus.com June 18, 2022 Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study  GuruFocus.com
• Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates - GuruFocus.com June 18, 2022 Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates  GuruFocus.com
• Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting - GuruFocus.com June 18, 2022 Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting  GuruFocus.com
• Inhibikase Therapeutics to Par - GuruFocus.com June 19, 2022 Inhibikase Therapeutics to Par  GuruFocus.com
• Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference - GuruFocus.com June 19, 2022 Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference  GuruFocus.com
• Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates - GuruFocus.com June 19, 2022 Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates  GuruFocus.com
• AbbVie Submits New Drug Application to US FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease - GuruFocus.com June 19, 2022 AbbVie Submits New Drug Application to US FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease  GuruFocus.com
• Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022 - GuruFocus.com June 19, 2022 Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022  GuruFocus.com
• Bioasis and Neuramedy Enter into Research Collaboration and License Agreement - GuruFocus.com June 19, 2022 Bioasis and Neuramedy Enter into Research Collaboration and License Agreement  GuruFocus.com
• Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium - GuruFocus.com June 19, 2022 Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium  GuruFocus.com